LIXTE Biotechnology Holdings
Setauket- East Setauket, New York, United States · Biotechnology, Energy, Health Care
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. Most cancer research over the past 30 years has focused on the "on" switches because the "off"
Key facts
- Headquarters
- Setauket- East Setauket, New York, United States
- Employees
- 2
- Industries
- Biotechnology, Energy, Health Care
- Status
- Public (NMAD)
- Website
- lixte.com
- Company page
Recent activity at LIXTE Biotechnology Holdings
- : SEC 8-K (7.01): On October 6, 2026, Nomad Power Solutions, Inc. announced the launch of its 2026 Nationwide Mobile Power Demonstration Tour. This initiative involves showcasing the company's flagship Voyager and Voyager Falcon transportable battery energy storage systems (BESS) across 26 locations in the Mountain West, Northeast, and Southwest regions during October and November. The tour aims to promote the company's innovative energy solutions and engage potential customers, highlighting strategic outreach to broaden their market presence.
- : SEC 8-K (1.01): On September 28, 2026, Nomad Power Solutions, Inc. entered into a Note Purchase Agreement with an Accredited Investor to issue a total of $6.57 million in Original Issue Discount Secured Promissory Notes. The company will receive $6.0 million in gross proceeds after an original issue discount of $540,000. Additionally, the company agreed to pay $30,000 to cover related fees. The Note has a maturity date of 12 months from the Purchase Price Date and bears an interest rate of 9% per year, with repayment terms that allow the Investor to exercise rights starting on the 6-month anniversary of the Purchase Price Date. This agreement is significant for the company as it provides essential funding for its operations.
- : SEC 8-K (7.01): On July 31, 2026, Nomad Power Solutions, Inc. announced through a press release that its common stock is now available for options trading on the Cboe Options Exchange under the symbol 'NMAD.' This marks a significant development for the Company, as it expands the trading options available to investors, potentially increasing liquidity and interest in its stock. The announcement is expected to enhance the company's visibility in the market, although no specific financial implications or conditions were disclosed in the release.
- : SEC 8-K (7.01): On July 8, 2026, Nomad Power Solutions, Inc. announced a significant capacity increase of its fleet-wide energy storage through a press release. This development indicates a strategic move to expand their operational capabilities and potentially enhance market competitiveness. The announcement aligns with ongoing efforts to improve energy solutions amidst growing demand for sustainable energy practices. The press release, attached as Exhibit 99.1, details the implications of this capacity increase on the company's future business operations and market position.
- : SEC 8-K (5.02): On July 1, 2026, the Board of the Company appointed John Travaglini to the Board, effective immediately, with a term expiring at the Company’s 2026 annual meeting of stockholders. Mr. Travaglini will participate in the Company’s standard non-employee director compensation program and will enter into a standard form of indemnification agreement. There are no arrangements or understandings regarding his selection, and no family relationships exist between Mr. Travaglini and any existing director or executive officer.
- : SEC 8-K (1.01):
- : SEC 8-K (1.01):
- : LIXTE to acquire NOMAD Transportable Power Systems
- : SEC 8-K (1.01): On June 2, 2026, Lixte Biotechnology Holdings, Inc. entered into a Securities Purchase Agreement with accredited investors for a registered direct offering of 2,366,503 shares of Common Stock and Pre-Funded Warrants to purchase 258,859 shares at $6.31 per share, generating gross proceeds of approximately $16.6 million. The offering closed on June 4, 2026, and was made under the company's existing shelf registration statement. The underwriting of this agreement could strengthen the company's financial positioning and support future growth initiatives.
- : SEC 8-K (5.02): On May 29, 2026, Lixte Biotechnology Holdings, Inc. appointed Stuart D. Porter to its Board of Directors, effective immediately, with his term set to expire at the 2026 Annual Meeting of Stockholders. Mr. Porter brings over 29 years of investment experience, having worked as a Founder and Managing Partner at Denham Capital. There are no arrangements or understandings affecting his selection, nor are there any reported transactions involving him that necessitate disclosure under Item 404(a) of Regulation S-K. This appointment signifies the Company's ongoing strategic transformation and potential shifts in governance that could impact its future direction.
Leadership
- Sidney Braun, Chief Executive Officer
- Peter Stazzone, Chief Financial Officer
- Jan Schellens, Chief Medical Officer
- Bas van der Baan, President
Verified email and direct lines for LIXTE Biotechnology Holdings’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
LIXTE Biotechnology Holdings in the news
- LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026 - Yahoo Finance (Jun 18, 2026)
- A Nasdaq Company Just Reinvented Itself as a Power Company — and Bet It All on the AI Energy Crunch - GlobeNewswire (Jun 18, 2026)
- From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch - PR Newswire Canada (Jun 12, 2026)
- LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment - Yahoo Finance (Apr 27, 2026)
- The AI Boom’s Real Bottleneck Is Power — and One Nasdaq Company Is Reinventing Itself to Solve It - GlobeNewswire (Jun 18, 2026)
- LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth - Yahoo Finance (Jun 03, 2026)
- LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - GlobeNewswire (Feb 18, 2026)
- LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Yahoo Finance (Apr 02, 2026)
Companies similar to LIXTE Biotechnology Holdings
- Sandbrook · Biotechnology, Energy, Health Care, Renewable Energy, Therapeutics
- Orthogon Therapeutics · Biotechnology, Health Care, Information Technology, Science And Engineering
- Enliven Therapeutics · Biotechnology, Health Care, Science And Engineering, Therapeutics
- Graphene & Solar Technologies Ltd · Energy, Renewable Energy, Science And Engineering, Solar
- Specific Biologics · Biotechnology, Health Care, Information Technology, Science And Engineering
About LIXTE Biotechnology Holdings: questions and answers
What does LIXTE Biotechnology Holdings do?
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. Most cancer research over the past 30 years has focused on the "on" switches because the "off"
Where is LIXTE Biotechnology Holdings headquartered?
LIXTE Biotechnology Holdings is headquartered in Setauket- East Setauket, New York, United States.
How many employees does LIXTE Biotechnology Holdings have?
LIXTE Biotechnology Holdings has about 2 employees.
Who leads LIXTE Biotechnology Holdings?
Sidney Braun is a Chief Executive Officer at LIXTE Biotechnology Holdings.
What is the latest news on LIXTE Biotechnology Holdings?
On Oct 06, 2026, SEC 8-K (7.01): On October 6, 2026, Nomad Power Solutions, Inc. announced the launch of its 2026 Nationwide Mobile Power Demonstration Tour. This initiative involves showcasing the company's flagship Voyager and Voyager Falcon transportable battery energy storage systems (BESS) across 26 locations i
Is LIXTE Biotechnology Holdings a public company?
Yes. LIXTE Biotechnology Holdings is publicly traded under the ticker NMAD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy